OPTIMUS-EL: Phase II Trials of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab Therapy (clinicaltrials.gov) - Sep 5, 2025 - P2 | N=40 | Not yet recruiting | Sponsor: Seoul National University Hospital | Initiation date: May 2025 ➔ Sep 2025
Trial initiation date • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Oncology
|